Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + dexamethasone
- Development stage
- Phase 4
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), and dexamethasone, a corticosteroid. This combination is used in multimodal analgesia to reduce opioid use and side effects in conditions like postoperative pain. Duloxetine has efficacy in chronic pain conditions, while dexamethasone enhances postoperative analgesia and reduces postoperative nausea and vomiting (PONV).
02
Targets
GR (Glucocorticoid receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on duloxetine + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duloxetine + dexamethasone.